JBPHF (Jacobio Pharmaceuticals Group Co) Revenue: $7.48 Mil (TTM As of Dec. 2025)


JBPHF Jacobio Pharmaceuticals Group Co Ltd JBPHF
54 GF Score
Price $0.87
GF Value $0.36
! 6 Warning Signs
View Full Analysis

What is Jacobio Pharmaceuticals Group Co Revenue?

Jacobio Pharmaceuticals Group Co JBPHF +4.52% 54 Revenue is $7.48 Mil as of Dec. 2025. GuruFocus rates JBPHF with a GF Score™ of 54/100 and a GF Value™ of $0.36. The stock has 6 warning signs investors should review.

Jacobio Pharmaceuticals Group Co's revenue for the six months ended in Dec. 2025 was $1.12 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $7.48 Mil. Jacobio Pharmaceuticals Group Co's Revenue per Share for the six months ended in Dec. 2025 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.

Warning Sign:

Jacobio Pharmaceuticals Group Co Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Jacobio Pharmaceuticals Group Co was -64.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was -18.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was -36.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 8 years, Jacobio Pharmaceuticals Group Co's highest 3-Year average Revenue per Share Growth Rate was -4.90% per year. The lowest was -61.00% per year. And the median was -18.80% per year.


Jacobio Pharmaceuticals Group Co  (OTCPK:JBPHF) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Jacobio Pharmaceuticals Group Co Revenue Related Terms


Jacobio Pharmaceuticals Group Co Revenue Historical Data

* Premium members only.

The historical data trend for Jacobio Pharmaceuticals Group Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobio Pharmaceuticals Group Co Revenue Chart

Jacobio Pharmaceuticals Group Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial 23.99 13.73 8.90 21.39 7.60

Jacobio Pharmaceuticals Group Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.25 0.00 21.39 6.36 1.12

JBPHF vs VRTX, REGN, ALNY: Revenue Comparison

For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jacobio Pharmaceuticals Group Co Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's Revenue distribution charts can be found below:

* The bar in red indicates where Jacobio Pharmaceuticals Group Co's Revenue falls into.


JBPHF
54GF Score
Jacobio Pharmaceuticals Group Co Ltd JBPHF
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jacobio Pharmaceuticals Group Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $7.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $7.48 Mil mean?
Jacobio Pharmaceuticals Group Co (JBPHF) has a Revenue of $7.48 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Jacobio Pharmaceuticals Group Co and its competitors.
Is Jacobio Pharmaceuticals Group Co's Revenue too high?
Jacobio Pharmaceuticals Group Co's current Revenue is $7.48 Mil. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Revenue compare to VRTX and REGN?
Jacobio Pharmaceuticals Group Co's Revenue of $7.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. Jacobio Pharmaceuticals Group Co's current Revenue is $7.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current Revenue of $7.48 Mil. The stock's GF Value™ is $0.36, compared to a current price of $0.87 — trading 141% above its estimated fair value. The current Revenue is $7.48 Mil. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Revenue is $7.48 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued. The current stock price of $0.87 is trading 141% above its estimated GF Value™ of $0.36.

Key valuation signals for JBPHF:

  • Revenue: $7.48 Mil
  • GF Value™: $0.36 vs. price of $0.87 (141% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jacobio Pharmaceuticals Group Co Business Description

Other Exchanges 01167:Hong Kong77V:Germany
Address No.105 Jinghai 3rd Road, Building 8, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score

Get the complete analysis for JBPHF

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.87
Price
$0.36
GF Value